Short-Term Benefit From Oral Vancomycin Treatment of Regressive-Onset Autism

By R. Sandler, S. Finegold, E. Bolte, C. P. Buchanan, A. P. Maxwell, M. Väisänen, M. Nelson, H. Wexler. Journal of Child Neurology, 2000

613 citations recorded by the source corpus.

Subfields: Cognitive Neuroscience, Infectious Diseases, Pharmacy

View Paper: https://www.semanticscholar.org/paper/58b68adadfce6dd5b086671d4e7b4e8afa181b3b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cognitive Neuroscience

1. Daniel H. Geschwind

In Infectious Diseases

1. B. B. Finlay
2. T. Borody
3. A. Khoruts
4. Elhanan Borenstein
5. L. Antunes
6. I. Sekirov
7. Janet K. Jansson
8. Shannon L. Russell

In Pharmacy

1. S. Mazmanian

Citations in the corpus

• Shifting the balance: antibiotic effects on host–microbiota mutualism (2011, background): “According to one study, oral vancomycin treatment actually reduces autistic symptoms in some patients, suggesting that certain gut microorganisms may influence the onset of this disorde”
• The Intestinal Microbiome in Early Life: Health and Disease (2014, background): “The microbiota composition may be of clinical importance, as a clinical study treated children with ASD with vancomycin and found a high efficacy of recovery from symptoms (243).”
• Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice (2019, background): “…foundational observations: first it was reported that oral vancomycin treat-ment resulted in a short-term benefit in a small group of children with ASD (Sandler et al., 2000), and subsequently, Finegold et al. (2002) surveyed gut bacteria in children with ASD and noted differences compared to TD…”
• Fecal Microbiota and Metabolome of Children with Autism and Pervasive Developmental Disorder Not Otherwise Specified (2013, background): “It was also hypothesized that Clostridium species were associated with AD symptomology [33–35] and that the spore forming property of Clostridia is one of the main concern for the reoccurrence of autistic symptoms after oral vancomycin treatments [9].”
• The role of microbiome in central nervous system disorders (2013, neutral): “Underlying mechanisms may involve the reduction of luminal LPS concentration (and thus potentially reduced chronic inflammation) and changes of CNS signals, such as hippocampal expression of BDNF (Ait-Belgnaoui et al., 2012; Bercik et al., 2011a; Sandler et al., 2000).”
• Gastrointestinal flora and gastrointestinal status in children with autism -- comparisons to typical children and correlation with autism severity (2011, background): “Additionally Desulfovibrio species and Bacteroides vulgatus were present in higher numbers in autistic than controls Treatment studies using a minimally absorbed oral antibiotic (vancomycin) to treat abnormal gut flora showed significant temporary improvements in behavior for children with late-onse”
• Pyrosequencing study of fecal microflora of autistic and control children. (2010, background): “Decreasing harmful populations with antibiotics like vancomycin has been shown to be an important step in improving late onset autism symptoms [8].”
• Reduced Incidence of Prevotella and Other Fermenters in Intestinal Microflora of Autistic Children (2013, background): “One study showed that in a small scale clinical setting, vancomycin treatment resulted in temporary improvement of autistic symptoms in children with late-onset autism [20].”